278 related articles for article (PubMed ID: 9627332)
1. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW
J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
[TBL] [Abstract][Full Text] [Related]
2. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging.
Brenner W; Klomp HJ; Bohuslavizki KH; Szonn B; Kampen WU; Henze E
Eur J Nucl Med; 1999 Dec; 26(12):1567-71. PubMed ID: 10638408
[TBL] [Abstract][Full Text] [Related]
3. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).
Maffioli L; Mascheroni L; Mongioj V; Gasparini M; Baldini MT; Seregni E; Castellani MR; Cascinelli N; Buraggi GL
J Nucl Med; 1994 Nov; 35(11):1741-7. PubMed ID: 7965150
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of 123iodine-ibzm scintigraphy for staging of malignant melanomas].
Henker C; Bida B; Markwardt J; Schlag P
Nuklearmedizin; 1997 Jan; 36(1):1-6. PubMed ID: 9082335
[TBL] [Abstract][Full Text] [Related]
5. Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT.
Booij J; Boot E; van Eeden S; van Amelsvoort T
Clin Nucl Med; 2011 Feb; 36(2):148-9. PubMed ID: 21220985
[TBL] [Abstract][Full Text] [Related]
6. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
[TBL] [Abstract][Full Text] [Related]
7. Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content.
Isiklar I; Leeds NE; Fuller GN; Kumar AJ
AJR Am J Roentgenol; 1995 Dec; 165(6):1503-12. PubMed ID: 7484597
[TBL] [Abstract][Full Text] [Related]
8. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
Leslie WD; Abrams DN; Greenberg CR; Hobson D
J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
[TBL] [Abstract][Full Text] [Related]
9. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
11. Sigma-receptor imaging by means of I123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer.
Everaert H; Flamen P; Franken PR; Verhaeghe W; Bossuyt A
Anticancer Res; 1997; 17(3B):1577-82. PubMed ID: 9179197
[TBL] [Abstract][Full Text] [Related]
12. Visualizing ocular melanoma using iodine-123-N-(2-diethylaminoethyl)4-iodobenzamide SPECT.
Everaert H; Bossuyt A; Flamen P; Mertens J; Franken PR
J Nucl Med; 1997 Jun; 38(6):870-3. PubMed ID: 9189131
[TBL] [Abstract][Full Text] [Related]
13. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).
Michelot JM; Moreau MF; Veyre AJ; Bonafous JF; Bacin FJ; Madelmont JC; Bussiere F; Souteyrand PA; Mauclaire LP; Chossat FM
J Nucl Med; 1993 Aug; 34(8):1260-6. PubMed ID: 8326382
[TBL] [Abstract][Full Text] [Related]
14. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
[TBL] [Abstract][Full Text] [Related]
15. Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzofurans with melanin.
Böni R; Steinert H; Böni RA; Lichtensteiger W; Dummer R; Hartman DS; von Schulthess GK; Burg G; Westera G
Dermatology; 1996; 193(3):198-202. PubMed ID: 8944340
[TBL] [Abstract][Full Text] [Related]
16. [123I]IBZM uptake in metastatic melanoma.
Maffioli LS; Mascheroni L; Clemente C; Baldini M; Castellani MR
J Nucl Biol Med (1991); 1993 Mar; 37(1):18-20. PubMed ID: 8329472
[TBL] [Abstract][Full Text] [Related]
17. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
18. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
[TBL] [Abstract][Full Text] [Related]
19. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
